Shenyang Xingqi Pharmaceutical announced that the company recently received the 'Pharmaceutical Registration Certificate' for Levocabastine Hydrochloride Eye Drops approved and issued by the National Medical Products Administration. This pharmaceutical is a multi-dose product, clinically indicated for treating eye itching related to allergic conjunctivitis. Currently, similar generic drugs have been approved for marketing domestically. The original research pharmaceutical was developed by Novartis Pharmaceuticals Corporation, imported into China in December 2020, with a concentration of 0.2%. The pharmaceutical approval number is valid until November 4, 2029.